A daily powder with 12 ingredients just posted some eye-catching vascular numbers in a randomized trial: better artery function, lower arterial stiffness, and a 6 mmHg drop in systolic blood pressure after six months. Cholesterol didn't budge, which means the small drop in estimated cardiovascular risk came from blood pressure, not lipids. But the trial was small, with only 43 of 61 participants finishing, and the manufacturer supplied the product and co-funded the work. Here's what the NOVOS Core results really show, what they don't, and who should think twice.
This page is available in